-
3 weeks ago | 
pharmacytimes.com | Steven Nissen |Alana Hippensteele
CommentaryArticleJune 2, 2025Author(s):,Bempedoic acid is an effective option for statin-intolerant patients or those needing additional low-density lipoprotein cholesterol (LDL-C) reduction, with clinical trials showing cardiovascular benefits, key drug-drug interaction considerations, and special management factors in patients with comorbidities.
-
2 months ago | 
hcplive.com | Steven Nissen
Author(s):Fact checked by:Steve Nissen, MD, discusses the phase 2 ALPACA trial and how it informs the potential of lepodisiran for lowering Lp(a). The ALPACA trial demonstrated lepodisiran, a long-acting small interfering RNA therapy, significantly and durably reduces lipoprotein(a) [Lp(a)] levels, with effects lasting up to 18 months.
-
Mar 27, 2025 | 
jamanetwork.com | Steven Nissen |Qiuqing Wang |Stephen Nicholls |Ann Marie Navar
Zerlasiran for the Treatment of Atherosclerotic Cardiovascular Disease—Reply Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a) Steven E. Nissen, MD; Qiuqing Wang, MS; Stephen J. Nicholls, MBBS, PhD; Ann Marie Navar, MD, PhD; Kausik K. Ray, MD, MPhil; Gregory G. Schwartz, MD, PhD; Michael Szarek, PhD; Erik S. G. Stroes, MD, PhD; Roland Troquay, MD; Jannick A. N. Dorresteijn, MD, PhD; Henry Fok, MBBS, PhD; David A.
-
Mar 27, 2025 | 
jamanetwork.com | Yumei Wu |Jiahao Meng |Shuguang Gao |Steven Nissen
Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a) Steven E. Nissen, MD; Qiuqing Wang, MS; Stephen J. Nicholls, MBBS, PhD; Ann Marie Navar, MD, PhD; Kausik K. Ray, MD, MPhil; Gregory G. Schwartz, MD, PhD; Michael Szarek, PhD; Erik S. G. Stroes, MD, PhD; Roland Troquay, MD; Jannick A. N. Dorresteijn, MD, PhD; Henry Fok, MBBS, PhD; David A.
-
Feb 27, 2025 | 
bottomlineinc.com | Steven Nissen |Robert Michelin
For people with high cholesterol, lifestyle modifications such as eating better, getting more exercise, losing weight and reducing stress can help curb cardiovascular risk…to some extent. But to substantially lower elevated cholesterol and its attendant risk for heart attack and stroke, long-term use of a prescription cholesterol-lowering medication may be necessary, says Cleveland Clinic cardiovascular disease expert Steven Nissen, MD.
-
Feb 13, 2025 | 
radcliffecvrm.com | Steven Nissen |Nisha Bansal |Antonio Ceriello |David Wheeler
Is BMI the best indicator to identify CVD patients who can be treated with GLP-1 RAs and other weight management therapies? In this short interview, Dr Steven Nissen (Cleveland Clinic, Cleveland, US) discusses how to determine which CVD patients will benefit most from treatment with GLP-1 RAs. He highlights how lifestyle changes are often ineffective in achieving weight loss goals, and therefore, collaboration between healthcare specialists is necessary to provide the best treatment option.
-
Nov 28, 2024 | 
radcliffecardiology.com | Harriette Van Spall |Steven Nissen |Marc P. Bonaca |Filippo L Gurgoglione
AHA Conference 2024 - Safety and efficacy outcomes of zerlasiran (Silence Therapeutics) in adults with elevated lipoprotein(a) at high risk of atherosclerotic cardiovascular disease events (ASCVD). Dr Steven Nissen (Cleveland Clinic, US) joins us onsite at AHA Conference to discuss the findings from ALPACAR (NCT05537571).
-
Nov 28, 2024 | 
radcliffecardiology.com | Harriette Van Spall |Steven Nissen |Stephen Nicholls |Marc P. Bonaca
AHA Conference 2024 - BROOKLYN: Safety and efficacy outcomes of obicetrapib (NewAmsterdam Pharma) alongside lipid-lowering therapy in Heterozygous Familial Hypercholesterolemia (HeFH) management. Dr Stephen Nicholls (Monash University and The Victorian Heart Hospital, Melbourne, AU) joins us onsite at AHA Conference to discuss the findings from BROOKLYN (NCT05425745).
-
Nov 28, 2024 | 
radcliffecardiology.com | Harriette Van Spall |Steven Nissen |Stephen Nicholls |Marc P. Bonaca
AHA Conference 2024 - Safety and efficacy outcomes of muvalaplin (Eli Lilly and Company) in adults with elevated lipoprotein(a) at high risk for cardiovascular events. Dr Stephen Nicholls (Monash University and The Victorian Heart Hospital, Melbourne, AU) joins us onsite at AHA Conference to discuss the findings from KRAKEN (NCT05563246).
-
Nov 26, 2024 | 
healio.com | Erik Swain |Richard Smith |Steven Nissen
Novel injectable agent lowers Lp(a) by more than 80% at 36 weeks• Zerlasiran lowered lipoprotein(a) by more than 80% at 36 weeks compared with placebo. • The results were sustained at 60 weeks, and there were no serious adverse events related to the study drug. CHICAGO — Zerlasiran, a novel injectable small interfering RNA molecule, lowered lipoprotein(a) by more than 80% compared with placebo at 36 weeks, according to the results of the ALPACAR trial.
